OUR MISSION

To empower clinicians and help patients with the best predictive information for personalized cancer care

OUR STORY

Profile image of ImpriMed's Co-founders, Sungwon Lim and Jamin Koo

ImpriMed co-founders Sungwon Lim and Jamin Koo met as undergraduates and discovered a shared passion for developing advanced technologies to improve the treatment of disease.  Both went on to complete PhDs in engineering sciences at Stanford University, where they decided to launch a startup company to tackle one of the greatest challenges in human disease: cancer.  

In 2017, Sungwon and Jamin founded ImpriMed to provide immediate solutions for cancer patients who need effective treatments today.

Rather than focusing on the development of new drugs for future patients, they built a platform that enables oncologists to quickly identify which of the available drugs can provide the best clinical outcomes for current patients. The ImpriMed platform combines quantitative high-throughput lab testing and artificial intelligence (AI) to provide healthcare providers with a comprehensive personalized drug prediction profile. Our AI models are trained using ImpriMed’s proprietary database of real-world clinical outcomes and a suite of lab tests that include our innovative ex vivo drug sensitivity assay that measures how a patient’s live tumor cells respond to a panel of anticancer drugs.  

A female veterinarian examining her canine patient
A black labrador retriever dog is licking his parent

We first launched the ImpriMed platform in the veterinary oncology space which moves at a significantly higher speed than the human oncology market and allows easy access to comprehensive patient data. ImpriMed has helped 200+ veterinary oncologists in 30 states to deliver personalized treatments to their canine lymphoma and leukemia patients. Apart from providing veterinarians with a cutting-edge tool to help man’s best friend, ImpriMed’s experience in the veterinary market has paved the way for the company to launch its validated platform into the human oncology space.

At ImpriMed, we are saving pet cancer patients now, and we will save pet parents next!

Our Team

A profile image of Sungwon Lim, CEO & Co-Founder at ImpriMed, Inc.
Co-Founder & CEO
Board Director

Sungwon Lim

A profile image of Jamin Koo, Director & Co-Founder at ImpriMed, Inc.
Co-Founder & Director
Board Director

Jamin Koo

A profile image of Mary Ocnean, Vice President of Commercial Operations at ImpriMed, Inc.
Vice President,
Commercial Operations

Mary Ocnean

Profile image of Ilona Holcomb, Director of Bioscience at ImpriMed, Inc.
Director, Bioscience

Ilona Holcomb

A profile image of John Callegari, Lead Data Scientist at ImpriMed, Inc.
Lead Data Scientist

John Callegari

A profile image of Raghavendra Pudupakam, Lead Research Scientist at ImpriMed, Inc.
Lead Research Scientist

Raghavendra Pudupakam

A profile image of Josephine Tsang, Senior Research Associate at ImpriMed, Inc.
Senior Research Associate

Josephine Tsang

A profile image of Stanley Park, Business Operations Manager at ImpriMed, Inc.
Business Operations Manager

Stanley Park

A profile image of Deanna Swartzfager, Veterinary Medical Assistant at ImpriMed, Inc.
Veterinary Medical Assistant

Deanna Swartzfager

A profile image of Peter Lee, Data Scientist at ImpriMed, Inc.
Data Scientist

Peter Lee

A profile image of Melody Jung, Marketing Designer at ImpriMed, Inc.
Marketing Designer

Melody Jung

A profile image of Heeju Choi, Software Engineer at ImpriMed, Inc.
Software Engineer

Heeju Choi

A profile image of Sheena Kapoor, Research Associate at ImpriMed, Inc.
Research Associate

Sheena Kapoor

A profile image of Han Bin Lee, Software Engineer at ImpriMed, Inc.
Software Engineer

Han Bin Lee

A profile image of Renee Sagnay, Marketing & Customer Support Assistant at ImpriMed, Inc.
Marketing & Customer Support Assistant

Renee Sagnay

A profile image of Jenna Zarbis, Business Operations Assistant at ImpriMed, Inc.
Business Operations Assistant

Jenna Zarbis

A profile image of Hojin Nam, Software Engineer at ImpriMed, Inc.
Software Engineer

Hojin Nam

Profile image of Collin Cavanuagh
Senior Sales Manager

Collin H. Cavanaugh

Profile image of Jerry Cromarty
Laboratory Technician

Jerry Cromarty

advisors & board directors

A profile image of Douglas H. Thamm, Scientific/Medical Advisor at ImpriMed, Inc.
Scientific/Medical Advisor

Douglas H. Thamm

VMD, DACVIM (Oncology)

Colorado State University

Barbara Cox Anthony Professor of Oncology
A profile image of Dr. Wendi Velando Rankin, Medical Advisor at ImpriMed, Inc.
Medical Advisor

Wendi Velando Rankin

DVM, DACVIM (Oncology)

SAGE

Chief Medical Officer
A profile image of Carlos Bustamante, Scientific Advisory Board at ImpriMed, Inc.
Scientific Advisory Board

Carlos Bustamante

PhD

Stanford University
School of Medicine

Professor
A profile image of Sean McDonald, Business Advisor & Board Director at ImpriMed, Inc.
Business Advisor & Board Director

Sean McDonald

MBA

Ocugenix

President & CEO
A profile image of Jinjoo Kim, Board Director at ImpriMed, Inc.
Board Director

Jinjoo Kim

MD, PhD

HG Initiative

Executive Director

Consultants

A profile image of Dr. Kevin Choy, Medical Oncology Consultant at ImpriMed, Inc.
Medical Oncology Consultant

Kevin Choy

DVM, MS, DACVIM (Oncology)
A profile image of Tariq Shah, Business Consultant at ImpriMed, Inc.
Business Consultant

Tariq Shah

A profile image of Hyun Goo Kang, Software Engineer Consultant at ImpriMed, Inc.
Software Engineer Consultant

Hyun Goo Kang

MS
A profile image of Dr. Robert Barthel, Software Engineer Consultant at ImpriMed, Inc.
Veterinary Science Consultant

Robert Barthel

DVM, PhD

Offices

Palo Alto Headquarters

4030 Fabian Way
Palo Alto, CA 94303
United States of America

info@imprimedicine.com

Seoul Office

128, Gasan Digital 1-ro
Geumcheon-gu, Seoul 08507
STX-V Tower, Room 209
Republic of Korea
imprimedkorea@imprimedicine.com

Join our growing team!